Globus Medical Completes Acquisition of Alphatec’s International Business
September 01 2016 - 4:15PM
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant
manufacturer, today announced that it has successfully completed
the previously announced acquisition of the international
operations and distribution channels of Alphatec Holdings, Inc., a
publicly traded medical devices company (Nasdaq:ATEC).
David Paul, Chairman and CEO said, “We were able
to close this transaction ahead of schedule thanks to the hard work
and cooperation of both companies involved. Strategically,
this acquisition gives us immediate access to Japan and increased
presence and penetration in other key geographies, and significant
scale, roughly doubling our international sales. In addition,
we will be acquiring a talent pool of international sales
professionals as well as an extensive network of international
distributors. We remain excited about the future growth potential
of our international business as a result of this transaction.”
As a result of the acquisition, Globus Medical
will assume Alphatec’s existing international direct and
distributor sales channels. Globus Medical intends to offer
its own products through these sales channels, but during the
transition, Globus Medical will continue to sell Alphatec
products. The transaction includes a supply agreement through
which Alphatec will supply its products to Globus Medical for up to
five years.
About Globus Medical,
Inc.Globus Medical, Inc. is a leading musculoskeletal
implant company based in Audubon, PA. The company was founded
in 2003 by an experienced team of professionals with a shared
vision to create products that enable surgeons to promote healing
in patients with musculoskeletal disorders.
Non-GAAP Financial MeasuresTo
supplement our financial statements prepared in accordance with
U.S. generally accepted accounting principles (“U.S. GAAP”),
management uses certain non-GAAP financial measures. For
example, non-GAAP Diluted Earnings Per Share represents diluted
earnings per share excluding the provision for litigation,
acquisition related items, and adjusted for the tax effects of such
adjustments. We believe this non-GAAP measure is a useful
indicator of our operating performance, and particularly as an
additional measure of comparative operating performance from period
to period as it removes the effects of litigation and acquisition
related items, which we believe are not reflective of underlying
business trends.
Non-GAAP Diluted Earnings Per Share is not
calculated in conformity with U.S. GAAP. Non-GAAP financial
measures have limitations as analytical tools and should not be
considered in isolation or as a substitute for financial measures
prepared in accordance with U.S. GAAP. These measures do not
include certain expenses that may be necessary to evaluate our
liquidity or operating results. Our definition of non-GAAP
Diluted Earnings Per Share may differ from that of other companies
and therefore may not be comparable.
Safe Harbor StatementsAll
statements included in this press release other than statements of
historical fact are forward-looking statements and may be
identified by their use of words such as “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan” and other similar terms. These
forward-looking statements are based on our current assumptions,
expectations and estimates of future events and trends.
Forward-looking statements are only predictions and are subject to
many risks, uncertainties and other factors that may affect our
businesses and operations and could cause actual results to differ
materially from those predicted. These risks and
uncertainties include, but are not limited to, factors affecting
our quarterly results, our ability to manage our growth, our
ability to sustain our profitability, demand for our products, our
ability to compete successfully (including without limitation our
ability to convince surgeons to use our products and our ability to
attract and retain sales and other personnel), our ability to
rapidly develop and introduce new products, our ability to develop
and execute on successful business strategies, our ability to
successfully integrate the international operations acquired from
Alphatec, both in general and on our anticipated timeline, our
ability to transition Alphatec’s international customers to Globus
Medical products, our ability to realize the expected benefits to
our results from the Alphatec acquisition, our ability to comply
with laws and regulations that are or may become applicable to our
businesses, our ability to safeguard our intellectual property, our
success in defending legal proceedings brought against us, trends
in the medical device industry, general economic conditions, and
other risks. For a discussion of these and other risks,
uncertainties and other factors that could affect our results, you
should refer to the disclosure contained in our most recent annual
report on Form 10-K filed with the Securities and Exchange
Commission, including the sections labeled “Risk Factors” and
“Cautionary Note Concerning Forward-Looking Statements,” and in our
Forms 10-Q, Forms 8-K and other filings with the Securities and
Exchange Commission. These documents are available at
www.sec.gov. Moreover, we operate in an evolving
environment. New risk factors and uncertainties emerge from
time to time and it is not possible for us to predict all risk
factors and uncertainties, nor can we assess the impact of all
factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking
statements. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on any forward-looking
statements. Forward-looking statements contained in this
press release speak only as of the date of this press
release. We undertake no obligation to update any
forward-looking statements as a result of new information, events
or circumstances or other factors arising or coming to our
attention after the date hereof.
Contact:
Daniel Scavilla
Senior Vice President, Chief Financial Officer
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Globus Medical (NYSE:GMED)
Historical Stock Chart
From Apr 2023 to Apr 2024